News

Oxygenta Pharmaceutical Ltd (Scrip Code: 524636) reported that details of securities dematerialized during the quarter ended September 30, 2026, have been furnished to stock exchanges as required under Regulation 74(5) of the SEBI [Depositories and Participants] Regulations, 2018, according to a filing with the BSE Limited on October 13, 2026, referencing a letter from M/s. Venture Capital and Corporate Investments Private Limited dated October 5, 2026.

Oxygenta Pharmaceutical Limited informed the BSE Limited that the trading window for dealing in the company`s securities will be closed from October 1, 2026, until 48 hours after the declaration of financial results for the quarter and half year ending September 30, 2026, for designated persons, their immediate relatives, and connected persons, in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015; a board meeting will be scheduled to consider and approve the financial results.

Oxygenta Pharmaceutical announced that the Annual General Meeting(AGM) of the company will be held on 21 August 2026.

Net Loss of Oxygenta Pharmaceutical reported to Rs 2.10 crore in the quarter ended June 2026 as against net loss of Rs 6.11 crore during the previous quarter ended June 2025. Sales rose 144.55% to Rs 37.00 crore in the quarter ended June 2026 as against Rs 15.13 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales37.0015.13 145 OPM %1.51-45.14 - PBDT-1.88-7.29 74 PBT-2.50-8.14 69 NP-2.10-6.11 66 Powered by Capital Market - Live News

Oxygenta Pharmaceutical has postponed the meeting of the Board of Directors which was scheduled to be held on 25 July 2026. The meeting will now be held on 27 July 2026.